CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2014—Abbott’s DNA test for the detection of high-risk human papillomavirus is now available in Europe. The test identifies women at increased risk for development of cervical cancer or the presence of high-grade disease.
The Abbott RealTime High Risk HPV test has been clinically validated in significant studies conducted in European countries in recent years and the intended use has been expanded to include first-line primary screening.
Abbott, 224-667-6100